Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction today announced successful completion of dosing af healthy subject in the Phase 1 clinical trial.
The Phase 1 trial, randomized, double-blind, placebo controlled single ascending dose in multiple cohorts of healthy subjects, has now been completed and we have reached expected clinically relevant dose levels. The preliminary readout from the phase 1 has demonstrated that IPED2015 in general is safe and well tolerated.
‘We are very pleased with the completion of the Phase 1 trial. We are